dilazep has been researched along with Kidney Diseases in 2 studies
Dilazep: Coronary vasodilator with some antiarrhythmic activity.
dilazep : A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Persson, P | 1 |
| Fasching, A | 1 |
| Pihl, L | 1 |
| Palm, F | 1 |
| Kuriyama, S | 1 |
| Tomonari, H | 1 |
| Hosoya, T | 1 |
2 other studies available for dilazep and Kidney Diseases
| Article | Year |
|---|---|
Adenosine reuptake inhibition reduces diabetes-induced glomerular hyperfiltration via the adenosine A2
Topics: Adenosine; Animals; Diabetes Mellitus; Dilazep; Glomerular Filtration Rate; Kidney; Kidney Diseases; | 2023 |
Antiplatelet therapy decreases the incidence of erythropoietin-induced hypertension in predialysis patients.
Topics: Adult; Aged; Anemia; Dilazep; Dipyridamole; Erythropoietin; Female; Hematocrit; Humans; Hypertension | 1999 |